HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy.

Abstract
In patients with acute myeloid leukemia (AML), rapid reduction of circulating blasts with induction chemotherapy may serve as an in vivo marker of chemosensitivity. We performed a retrospective analysis of 363 patients with untreated AML who received induction chemotherapy in order to determine the relationship between day of blast disappearance (DOBD) and complete remission (CR) rates, event-free survival (EFS), and overall survival (OS). DOBD ≤ 5 vs. >5 was identified as the most discriminating cutoff for OS. DOBD > 5 was observed in 35 patients (9.6%). The CR rate for patients with DOBD ≤ 5 vs. >5 was 74.0 and 28.6%, median EFS was 9.4 and 1.8 months, and median OS was 17.1 and 5.8 months, respectively (P < 0.001 for all). DOBD > 5 was independently associated with a lower CR rate and shorter EFS and OS (P < 0.001 for all). DOBD > 5 retained prognostic significance for EFS and OS when patients were stratified by cytogenetic risk group, de novo vs. secondary or therapy-related AML, European LeukemiaNet-based risk groups, and whether CR was achieved. We propose DOBD > 5 as a simple and early marker of disease resistance that identifies patients with poor prognosis who otherwise may not be identified with existing risk stratification systems. Am. J. Hematol. 91:1221-1226, 2016. © 2016 Wiley Periodicals, Inc.
AuthorsNicholas J Short, Christopher B Benton, Hsiang-Chun Chen, Peng Qiu, Lisa Gu, Sherry Pierce, Mark Brandt, Abhishek Maiti, Taejin L Min, Kiran Naqvi, Alfonso Quintas-Cardama, Marina Konopleva, Tapan Kadia, Jorge Cortes, Guillermo Garcia-Manero, Farhad Ravandi, Elias Jabbour, Hagop Kantarjian, Michael Andreeff
JournalAmerican journal of hematology (Am J Hematol) Vol. 91 Issue 12 Pg. 1221-1226 (12 2016) ISSN: 1096-8652 [Electronic] United States
PMID27474808 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Copyright© 2016 Wiley Periodicals, Inc.
Chemical References
  • Biomarkers
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers (blood)
  • Blast Crisis (blood, mortality, pathology)
  • Disease-Free Survival
  • Humans
  • Induction Chemotherapy (methods)
  • Leukemia, Myeloid, Acute (diagnosis, drug therapy, mortality, pathology)
  • Middle Aged
  • Prognosis
  • Remission Induction (methods)
  • Retrospective Studies
  • Risk Factors
  • Survival Analysis
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: